



AHAM World Series - Biotechnology Fund

A feeder fund that seeks to achieve capital appreciation over medium to long term period through investments in biotechnology and biotechnology-related companies worldwide.

Fund Category
Feeder (Wholesale)

Fund Type
Growth

Target Fund Manager
Janus Henderson Investors Europe S.A.

Target Fund
Janus Henderson Horizon Fund – Biotechnology Fund

Benchmark
N/A

Base Currency
USD

Launch Date / IOP
May 30, 2024 / USD0.50(USD)
May 30, 2024 / MYR0.50(MYR)
May 30, 2024 / MYR0.50(MYR Hedged)

Financial Year End
October 31

Subscription
Cash

Initial Sales Charge
Max 5.50% of the NAV per Unit

Annual Management Fee
Max 1.80% per annum

**Minimum Investment /
Minimum Subsequent Investment**
USD 10,000 / USD 5,000(USD)
MYR 30,000 / MYR 10,000(MYR)
MYR 30,000 / MYR 10,000(MYR Hedged)

As at June 30, 2026*
Fund Size / NAV Per Unit
USD 1.2million / USD 0.8502(USD)
MYR 8.6million / MYR 0.8137(MYR Hedged)
MYR 3.9million / MYR 0.7369(MYR)

Performance Record as at June 30 2026*



July, 2024 to June, 2026 NAV-NAV prices and assuming reinvestment of distributions into the Fund, gross investment based in USD. The value of Units may go down as well as up. Past performance is not indicative of future performance.
Source: MorningStar

Performance Table as at June 30 2026*

Total Return (%)	1 Month	1 Year	3 Year	Since Inception
Fund (USD)	12.1	79.8	-	70.0
Fund (MYR)	15.5	74.5	-	47.4
Fund (MYR Hedged)	12.0	76.9	-	62.7

Annualised Return (%)	1 Year	3 Year	5 Year	Since Inception
Fund (USD)	79.8	-	-	30.5
Fund (MYR)	74.5	-	-	21.5
Fund (MYR Hedged)	76.9	-	-	27.7

Calendar Year Return (%)	Year To Date	2025	2024	2023
Fund (USD)	16.8	49.3	-	-
Fund (MYR)	17.5	35.5	-	-
Fund (MYR Hedged)	15.8	45.9	-	-

Source: MorningStar


Target Fund Top Holdings as at May 31 2026#

Equities	%
Praxis Precision Medicines	6.4
Revolution Medicines	4.6
BridgeBio Pharma	4.3
Argenx	4.0
Vertex Pharmaceuticals	3.8
United Therapeutics	3.8
Gilead Sciences	3.8
Miram Pharmaceuticals	3.4
PTC Therapeutics	3.3
Regeneron Pharmaceuticals	3.3

Asset Allocation as at June 30 2026*

Janus Henderson Horizon Fund – Biotechnology Fund	100.2%
Class A2 (USD)	
Cash & Cash Equivalents	-0.2%


Target Fund Sector Allocation as at May 31 2026#



Income Distribution History

Distribution Policy: The fund will distribute income subject to the availability of income.
Incidentally: MYR, USD, MYR Hedged

Target Fund Country Allocation as at May 31 2026#



* The data provided above is that of the Fund and is a percentage of NAV as at June 30 2026. All figures are subject to frequent changes on a daily basis and the percentages might not add up to 100% due to rounding.

The data provided above is that of the Fund by Janus Henderson Investors Europe S.A. and is a percentage of NAV of the Target Fund as at May 31 2026 as the data is provided by Target Fund Manager after AHAM Capital publication cut-off date. Please note that asset exposure for the Target Fund is subject to frequent changes on daily basis and the percentages might not add up to 100% due to rounding.

To invest in a Class other than MYR Class and/or MYR-Hedged Class, investors are required to have a foreign currency account with any Financial Institution as all transactions relating to the particular foreign currency will ONLY be made via telegraphic transfer.

Where a distribution is declared, investors are advised that following the issue of additional Units/distribution, the NAV per Unit will be reduced from cum-distribution NAV to ex-distribution NAV.

A copy of the Information Memorandum and Product Highlights Sheet ("PHS") can be obtained at AHAM Asset Management's ("AHAM Capital") sales offices or at www.aham.com.my. Investors are advised to read and understand the contents of Information Memorandum and the corresponding PHS before investing. There are fees and charges involved when investing in the Fund. Investors are advised to consider and compare the fees and charges as well of the risks carefully before investing. Investors should make their own assessment of the risks involved in investing and should seek professional advice, where necessary. The price of units and distribution payable, if any, may go down as well as up and past performance of the fund should not be taken as indicative of its future performance. The Securities Commission Malaysia has not reviewed this marketing/promotional material and takes no responsibility for the contents of this marketing/promotional material and expressly disclaims all liability, however arising from this marketing/promotional material.